RLMD - Relmada Therapeutics GAAP EPS of -$1.80 beats by $0.04 March, 23 2022 04:25 PM Relmada Therapeutics Inc. Relmada Therapeutics press release (NASDAQ:RLMD): Q4 GAAP EPS of -$1.80 beats by $0.04. Cash cash equivalents, and short term investment of $211.9M For further details see: Relmada Therapeutics GAAP EPS of -$1.80 beats by $0.04